Sanofi
SNY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001121404
No open-market purchases or sales by Sanofi insiders were filed in the last 90 days; 718 institutions reported holding it in 13F filings for Q2 2026, worth $8.08B in total; Maverick Capital is the only superinvestor holding it.
Other share classesSNYNF
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −14 vs. previous quarter
- 718
- 13F valueReported value at the end of Q2 2026
- $8.08B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding SNY, Q2 2026
1 superinvestor reports holding Sanofi on Form 13F. Percentages are the stock's share of each portfolio.
Latest insider trades
Open-market purchases and sales by Sanofi insiders from Form 4, newest first.
No open-market purchases or sales by Sanofi insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in Sanofi at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Dodge & Cox | 28,088,274 | $1.20B | 0.63% | −1,416,358−4.8% | Reduced |
| Morgan Stanley | 10,702,527 | $456.6M | 0.02% | −1,809,340−14.5% | Reduced |
| Fisher Asset Management, LLC | 10,627,088 | $453.4M | 0.13% | −815,075−7.1% | Reduced |
| Bank of America Corp | 8,008,572 | $341.6M | 0.02% | −1,475,778−15.6% | Reduced |
| Invesco Ltd. | 6,798,961 | $290.0M | 0.02% | +177,422+2.7% | Added |
| JPMorgan Chase & Co | 6,573,682 | $285.5M | 0.02% | +972,951+17.4% | Added |
| Mondrian Investment Partners LTD | 5,522,564 | $235.6M | 4.24% | +482,499+9.6% | Added |
| Brandes Investment Partners, LP | 4,136,417 | $176.5M | 1.24% | +413,317+11.1% | Added |
| Federated Hermes, Inc. | 3,849,802 | $164.2M | 0.24% | −904,557−19.0% | Reduced |
| Boston Partners | 3,844,844 | $164.0M | 0.15% | +245,560+6.8% | Added |